GN-CORPORATION
19.10.2021 08:48:06 CEST | Business Wire | Press release
Alfred Patisenah and Daisy Ramadhani of School of Life Sciences and Technology, Indonesia, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2021, on stem cells and regenerative medicine, in a fiercely fought contest among teams representing NIMHANS, Bangalore, India and Kasturba Medical College, the defending champions. Rajalakshmi Engineering College represented by Vigneshwar Ranjan and Vasanta Vaarshini Umapathi came runners in this contest across in three stages with assignments and online live quizzing, conducted since 2006, every October to commemorate the inaugural anniversary of Nichi in Centre for Regenerative Medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018006087/en/
The virtual event had lectures by Prof. Gary Levy , founder, Training program in regenerative medicine, University of Toronto (www.regenmedcanada.com ) on lessons learnt during the pandemic and arenas of research for tackling future Covid-19 like viruses (https://www.springer.com/gp/book/9781461357759 ), Prof. Kazutoshi Mori , Kyoto University, a Lasker prize awardee (https://www.nature.com/articles/nm.3682 ) on unfolding protein response and endoplasmic reticulum stress (https://elifesciences.org/articles/60970 ) and Prof. Timothy Kieffer , University of British Columbia & CSO of Viacyte Inc., on encapsulated pancreatic islet cell transplantation for diabetes (https://doi.org/10.3389/fendo.2021.642152 ). Covid-19 related research were presented by Dr. Tomohiko Kisaka, Hiroshima University, Dr. Stanley Jeremiah, Yokohama City University (https://jamanetwork.com/journals/jama/fullarticle/2765837 ), Dr. K. Raghavan, JAICARE, Madurai, India (https://www.sciencedirect.com/science/article/pii/S0753332221010271 ), Dr. K. Ramesh Shankar, NHS Trust - Lincolnshire Partnership, London United Kingdom (https://www.jns-journal.com/article/S0022-510X(21)00248-3/fulltext ) and Dr Dedeepiya Devaprasad, who spoke on BREW-COCO method for early prediction of worsening outcome in Covid-19. Prof. Jurgen Hescheler, University of Cologne, Germany, Prof. Naoki Yamamoto, Emeritus Professor, National Centre for Global health and Medicine, Tokyo, Japan and Prof. Pushkala Subramaniam, TN MGR Medical University, India, moderated.
NCRM NICHE an inter-disciplinary event cum innovation platform, spearheading development of novel solutions for Non-alcoholic steatohepatitis (NASH or NAFLD : https://doi.org/10.1101/2021.07.08.451700 ) and for managing neurodevelopmental disorders like Autism Spectrum Disorders (https://doi.org/10.1101/2021.06.28.21259619 ), has started attracting multinational investors. Enso Healthcare DMCC, Dubai, UAE, who have partnered with GN Corporation for this active knowledge gaining academic event, being a part of Enso group, a global conglomerate with diverse interests is envisaging to develop path breaking solutions through futuristic research for prevention and management of lifestyle illnesses and in the domains of anti-aging and longevity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018006087/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release
Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom